Fate Therapeutics, Inc. (NASDAQ:FATE) Stake Lessened by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D cut its stake in Fate Therapeutics, Inc. (NASDAQ:FATEGet Rating) by 19.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,216 shares of the biopharmaceutical company’s stock after selling 19,127 shares during the period. State of New Jersey Common Pension Fund D owned approximately 0.08% of Fate Therapeutics worth $1,775,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. National Bank of Canada FI acquired a new stake in Fate Therapeutics during the second quarter valued at approximately $25,000. Kessler Investment Group LLC purchased a new stake in shares of Fate Therapeutics in the 3rd quarter valued at approximately $82,000. Virtus ETF Advisers LLC lifted its position in shares of Fate Therapeutics by 80.1% in the 2nd quarter. Virtus ETF Advisers LLC now owns 5,566 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 2,475 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of Fate Therapeutics in the 1st quarter valued at approximately $180,000. Finally, Quantamental Technologies LLC purchased a new stake in shares of Fate Therapeutics in the 2nd quarter valued at approximately $211,000.

Insider Buying and Selling at Fate Therapeutics

In other Fate Therapeutics news, insider Bahram Valamehr sold 10,917 shares of the stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $5.24, for a total value of $57,205.08. Following the completion of the sale, the insider now directly owns 168,917 shares of the company’s stock, valued at approximately $885,125.08. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Bahram Valamehr sold 10,917 shares of the firm’s stock in a transaction dated Tuesday, January 10th. The shares were sold at an average price of $5.24, for a total transaction of $57,205.08. Following the completion of the transaction, the insider now directly owns 168,917 shares of the company’s stock, valued at approximately $885,125.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Cindy Tahl sold 11,553 shares of the firm’s stock in a transaction dated Tuesday, January 10th. The stock was sold at an average price of $5.24, for a total transaction of $60,537.72. Following the transaction, the general counsel now directly owns 177,598 shares of the company’s stock, valued at $930,613.52. The disclosure for this sale can be found here. Insiders sold a total of 75,708 shares of company stock valued at $396,710 in the last ninety days. Company insiders own 17.34% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on FATE shares. Guggenheim downgraded shares of Fate Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 3rd. Citigroup dropped their price objective on shares of Fate Therapeutics from $87.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, November 16th. SVB Leerink dropped their price objective on shares of Fate Therapeutics from $62.00 to $10.00 and set an “outperform” rating on the stock in a research note on Friday, January 6th. Canaccord Genuity Group started coverage on shares of Fate Therapeutics in a research note on Monday, October 10th. They issued a “buy” rating and a $42.00 price objective on the stock. Finally, Stifel Nicolaus lowered shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 6th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $36.50.

Fate Therapeutics Trading Down 3.2 %

NASDAQ:FATE opened at $5.47 on Friday. Fate Therapeutics, Inc. has a 1 year low of $4.02 and a 1 year high of $43.14. The firm’s fifty day simple moving average is $13.81 and its 200 day simple moving average is $21.94. The firm has a market capitalization of $531.52 million, a PE ratio of -1.79 and a beta of 1.74.

Fate Therapeutics (NASDAQ:FATEGet Rating) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.07. Fate Therapeutics had a negative net margin of 425.99% and a negative return on equity of 48.78%. The business had revenue of $14.98 million for the quarter, compared to analyst estimates of $15.34 million. As a group, analysts anticipate that Fate Therapeutics, Inc. will post -3.22 EPS for the current fiscal year.

Fate Therapeutics Company Profile

(Get Rating)

Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D.

Recommended Stories

Want to see what other hedge funds are holding FATE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fate Therapeutics, Inc. (NASDAQ:FATEGet Rating).

Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.